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Abstract Alzheimer disease is characterized by a specific type
of neuronal degeneration in which the microtubule associated
protein d is abnormally hyperphosphorylated causing the
disruption of the microtubule network. We have found that the
phosphorylation of human d (d3L) by A-kinase, GSK-3 or CK-1
inhibits its microtubule assembly-promoting and microtubule-
binding activities. However, the inhibition of these activities of d
by GSK-3 is significantly increased if d is prephosphorylated by
A-kinase or CK-1. The most potent inhibition is observed by
combination phosphorylation of d with A-kinase and GSK-3.
Under these conditions, only very few microtubules are seen by
electron microscopy. Sequencing of 32P-labeled trypsin phos-
phopeptides from d prephosphorylated by A-kinase (using
unlabeled ATP) and further phosphorylated by GSK-3 in the
presence of [Q-32P]ATP revealed that Ser-195, Ser-198, Ser-199,
Ser-202, Thr-205, Thr-231, Ser-235, Ser-262, Ser-356 and Ser-
404 are phosphorylated, whereas if d is not prephosphorylated by
A-kinase, GSK-3 phosphorylates it at Thr-181, Ser-184, Ser-
262, Ser-356 and Ser-400. These data suggest that (i) pre-
phosphorylation of d by A-kinase makes additional and different
sites accessible for phosphorylation by GSK-3; (ii) phosphoryla-
tion of d at these additional sites further inhibits the biological
activity of d in its ability to bind to microtubules and promote
microtubule assembly. Thus a combined role of A-kinase and
GSK-3 should be considered in Alzheimer neurofibrillary
degeneration.
z 1998 Federation of European Biochemical Societies.
Key words: Alzheimer disease; Tau phosphorylation;
Microtubule assembly; Glycogen synthase kinase-3; Protein
kinase A; Microtubule associated protein tau-1
1. Introduction
Alzheimer disease is characterized histopathologically by
the presence of intraneuronal neuro¢brillary tangles and the
extracellular deposition of L-amyloid in the cerebral cortex,
especially the hippocampus. The neuro¢brillary tangles are
made up of paired helical ¢laments (PHFs), the major protein
subunit of which is the abnormally phosphorylated and gly-
cosylated microtubule associated protein d [1^3]. Two func-
tions have been described for d based on its ability to interact
with tubulin: the microtubule assembly promoting activity in
vitro [4,5] and the microtubule stabilizing activity in vivo [6].
Phosphorylation of d depresses its ability to promote the in
vitro assembly of microtubules [7]. Alzheimer abnormally
phosphorylated d is not only microtubule assembly incompe-
tent [8^10], but also inhibits assembly and disassembles the
preassembled microtubules in vitro [11^13]. In the tangle-
bearing neurons in Alzheimer disease brain, the normal cyto-
skeleton is disrupted and replaced with PHFs. Thus it is likely
that the abnormal hyperphosphorylation of d in Alzheimer
disease brain leads to the depolymerization of microtubules,
impaired axonal transport and neuronal degeneration [13].
The protein kinases involved and the phosphorylation sites
responsible for this malfunction of d are currently not under-
stood. Phosphorylation at Ser-262 is reported to cause the
decreased microtubule binding of d [14,15]. However, phos-
phorylation of Ser-262 only induces about 40% inhibition in
microtubule binding activity [16], suggesting that phosphoryl-
ation of other sites is necessary to completely inhibit its bio-
logical activity. The e¡ect of these phosphorylations on the
biological activity of d and the sites phosphorylated are, how-
ever, not known.
Twenty-one phosphorylation sites in PHF-d have been iden-
ti¢ed using reactivity with antibodies to various phosphoryla-
tion sites and protein sequencing techniques. Among them, 10
sites are on Ser/Thr-Pro motifs and 11 are on non-Ser/Thr-Pro
motifs (see [17,18]). The Ser/Thr-Pro and non-Ser/Thr-Pro
sites are probably phosphorylated by proline-dependent pro-
tein kinases (PDPKs) and non-PDPKs, respectively. The var-
ious PDPKs and non-PDPKs that can phosphorylate d in-
clude MAP kinase [19,20] cdc-2 kinase [21], cdk-2, cdk-5
[22] and GSK-3 [23^25]. The non-PDPKs include A-kinase
[26^28], C-kinase [27^30], CaM kinase II [27,28,31], CK-1
[27,28] and CK-2 [27,32]. The interaction of PDPK and
non-PDPK in d hyperphosphorylation has been reported
[28,33]. However, the e¡ects of these combination phosphoryl-
ations on the biological activity of d and the sites phosphory-
lated were not mapped.
In the present study, we have investigated the e¡ect of
phosphorylation of d by individual kinase or combination of
kinases on the biological activity of d and mapped the corre-
sponding sites phosphorylated by these kinases.
2. Materials and methods
2.1. Isolation of d, CK-1, GSK-3 and protein determination
Human d3L (cDNA kindly provided by M. Goedert), that has three
tandem C-terminal repeats plus two 29-amino acid N-terminal inserts
was expressed in E. coli and the protein isolated from the bacterial
lysate as described previously [16]. CK-1 [34] and GSK-3 [35] were
puri¢ed from bovine brain as previously described. The GSK-3 prep-
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aration contained both the K and L isoforms in the ratio 1:3. The
catalytic subunit of A-kinase was purchased from Sigma Chemical (St.
Louis, MO, USA). One unit of either CK-1 or GSK-3 is de¢ned as the
amount of kinase required to catalyze the incorporation of 1 nmol 32P
per min at 30‡C into dephosphocasein (4 mg/ml) or myelin basic
protein (1 mg/ml), respectively. Protein was estimated by the modi¢ed
Lowry method [36].
2.2. Phosphorylation of d
Human d3L was separately incubated in the absence or presence of
CK-1 (400 munits/ml), A-kinase (6 Wg/ml) and GSK-3 (350 munits/ml)
in a reaction mixture containing 1 mg/ml of d, 7 mM MgCl2, 12 mM
2-mercaptoethanol, 0.5 mM ATP, 20 mM HEPES (pH 7.5). Reaction
was initiated by the addition of kinase. After incubation at 30‡C for
2 h, the reaction was stopped by heating at 95‡C for 5 min and
denatured kinase removed by centrifugation (10 000Ug for 10 min).
The phosphorylated heat-stable d was also further phosphorylated
with GSK-3 for 4 h at 30‡C. In order to determine the stoichiometry
of phosphorylation in parallel d was phosphorylated using identical
conditions as above except [Q-32P]ATP.
2.3. Preparation of 32P-labeled tryptic phosphopeptides
d (300 Wg) was phosphorylated as described above by A-kinase and
non-radioactive ATP followed by GSK-3 and [Q-32P]ATP (2000 cpm/
pmol). In parallel d incubated without any kinase and heat treated
was then phosphorylated by GSK-3 as above. d was then precipitated
with 30% cold trichloroacetic acid and collected by centrifugation at
15 000Ug at 4‡C for 5 min. The pellets were washed twice with 0.5 ml
of 20% trichloroacetic acid and twice with 0.5 ml 80% acetone. The
washed pellets were resuspended in 0.15 ml of 50 mM ammonium
bicarbonate bu¡er, pH 8.0, containing 250 Wg TPCK-treated trypsin
and incubated at 37‡C for 12 h. Additional aliquots of trypsin (20 Wg
each) were added to the reaction mixture at 12 h and 24 h. At 36 h a
¢nal 10 Wg trypsin was added and the incubation continued for an-
other 4 h. The trypsin digests of [32P]-d were diluted with 3 ml bu¡er
A (0.1 M acetic acid/NaOH, pH 3.1) and then applied to the Fe3
a⁄nity column prepared according to Andersson and Porath [37]. A
1-ml bed column volume of Chelating Sepharose Fast Flow (Pharma-
cia Biotech) was washed with ¢ve column volumes of distilled water
and charged with ¢ve column volumes of 50 mM FeCl3 solution. The
column was then equilibrated with ¢ve column volumes of bu¡er A.
After absorption of the sample, the column was washed with bu¡er A,
and consecutively eluted with 0.1 M sodium acetate (pH 5.0), 1%
ammonium acetate (pH 6.3), 1% ammonium acetate (pH 7.2), 1%
ammonium acetate (pH 8.5) and 0.2 M EDTA (pH 8.0), respectively.
The fractions eluted at pH 8.5 were pooled and concentrated by a
Speed-Vac concentrator (Savant). The phosphopeptides were resus-
pended in 0.15 ml of deionized water, followed by centrifugation at
16 000Ug in ultra free Millipore tubes containing a ¢lter that retained
peptides of Mrs 10 000. The peptides in the ¢ltrate were then loaded
onto a reverse-phase C18 HPLC column (0.46U25 cm) and eluted
with a linear gradient of 0^35% acetonitrile (0.5% acetonitrile/min)
in 0.1% tri£uoroacetic acid (TFA) using Waters HPLC system. The
£ow rate was 1 ml/min and 0.3-ml fractions were collected. 32P-labeled
peaks were detected by counting (Cerenkov cpm) aliquots from frac-
tions in a liquid scintillation spectrophotometer.
2.4. Amino acid sequence analysis and mapping of phosphorylation sites
Radio-sequencing of 32P-labeled phosphopeptides was performed
by sequential manual Edman degradation as essentially described by
Laursen and Machleidt [38]. The 32P-peptide fractions eluted from
RPLC were resuspended in 50% acetonitrile and loaded on Sequelon
AA Disk (Sequelon AA Reagent Kit, GEN920033, Millipore). The N-
terminal amino acid was derivatized with PITC and cleaved with
TFA. The 32P radioactivity released from each cycle of the Edman
degradation was determined by Cerenkov counting. Aliquots of the
same phosphopeptides were subjected to amino acid sequencing by an
automated gas-phase sequencer as described previously [39]. The
phosphorylated sites were then identi¢ed by matching the 32P peaks
from manual radio-sequencing with the amino acid sequences deter-
mined by automated gas-phase sequencing.
2.5. Phosphoamino acid analysis
The phosphopeptides isolated from tryptic digests of 32P-d protein
were hydrolyzed in 6 N HCl under N2 at 110‡C for 2 h. The hydro-
lysate was then subjected to high voltage electrophoresis in the ¢rst
dimension on TLC plate in formic acid/acetic acid/H2O (50:160:1794,
v/v), pH 1.9, at 1.5 kV and 20‡C for 25 min, and the second-dimen-
sional electrophoresis in acetic acid/pyridine/H2O (10:1:189, v/v), pH
3.5, at 1.3 kV for 20 min followed by autoradiography. The position
of the phosphorylated amino acids in the plates were localized by
ninhydrin staining of the phosphorylated amino acid standards.
2.6. In vitro assembly of microtubule and negative stain electron
microscopy
d (20 Wg/ml) that was incubated in the absence or presence of di¡er-
ent kinases as described above, was mixed at 37‡C in 1-cm quartz
microcuvettes with freshly isolated tubulin (see below; 2 mg/ml) in an
assembly bu¡er containing 100 mM MES, 1 mM EGTA and 1 mM
GTP. The assembly was followed up to 10 min by recording the
turbidity changes at 350 nm in a Cary 1 spectrophotometer. At the
end of the assembly reaction, aliquots of the incubation mixture were
examined by negative stain microscopy as described previously for
microtubules [9,40].
2.7. Preparation of taxol-stabilized microtubules and microtubule
binding assay
Rat brain tubulin was isolated through two temperature-dependent
cycles of microtubule polymerization-depolymerization [41] followed
by removal of the microtubule-associated proteins (MAPs) by phos-
phocellulose ion-exchange chromatography [42]. Taxol-stabilized mi-
crotubules were prepared by incubating MAPs-free tubulin (V4 mg/
ml) with taxol (20 WM) in the presence of 1 mM of PMSF at 37‡C for
30 min. The microtubules were collected by centrifugation for 30 min
at 50 000Ug at 32‡C. For microtubule binding assay, non-phosphory-
lated or phosphorylated d (10 Wg/ml) was incubated with taxol-stabi-
lized microtubules (0.4 mg/ml) at 37‡C for 30 min in a bu¡er contain-
ing 0.1 M HEPES (pH 6.8), 2 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM PMSF, 20 WM taxol and 1 mM GTP. Microtubule-
associated d and unbound d were separated by centrifugation at
50 000Ug for 30 min at 32‡C over 125 mM sucrose cushion. The
pellet (in the sucrose cushion) was washed once with water. The
two combined supernatants and the pellet were dried in a Speed-
Vac concentrator. The samples were resuspended in Laemmli sample
bu¡er and electrophoresed on a 10% SDS-polyacrylamide gel. The
blots were developed with the polyclonal anti-d primary antibody
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Fig. 1. Inhibition of microtubule assembly promoting activity of d
phosphorylated by various kinases. d was phosphorylated with the
individual kinases A-kinase, GSK-3 and CK-1, or CK-1 plus GSK-
3, A-kinase plus GSK-3 combinations as described in Section 2; d,
identically treated but without any kinase served as a control. Mi-
crotubule assembly was carried out by incubating at 37‡C rat brain
tubulin (2 mg/ml) with d (20 Wg/ml). Microtubule assembly promot-
ing activity was inhibited by all the kinase-treated d samples. The
most potent inhibition was seen in the combination phosphorylation
of d by A-kinase plus GSK-3. The curves show microtubule assem-
bly in the presence of d treated with no kinase, d phosphorylated
with CK-1, GSK-3, A-kinase alone, d phosphorylated with CK-1
plus GSK-3, A-kinase plus GSK-3 and assembly with tubulin alone.
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92e (1:5000 dilution [43]) and 125I-labeled donkey anti-rabbit second-
ary antibody (0.1 Wg/ml). Blots were quantitatively analyzed with the
aid of a computerized bioimage analyzer (Fuji BAS-1500).
3. Results
3.1. Inhibition of microtubule assembly and microtubule
binding activities of d by phosphorylation
In two hours, the 32P incorporation by CK-1, A-kinase and
GSK-3 was determined to be 3.4, 1.1 and 1.2 mol/mol of d,
respectively. The subsequent 32P incorporation by GSK-3 in 4
h was 1.5 and 3.2 mol/mol in d prephosphorylated by CK-1
and A-kinase, respectively. We examined the e¡ect of the
phosphorylation of human d3L by various kinases on its mi-
crotubule assembly-promoting and microtubule-binding activ-
ities. When acting singly, d phosphorylated by the di¡erent
kinases inhibited microtubule assembly in the order A-kina-
sesGSK-3sCK-1-phosphorylated d (Fig. 1). A greater in-
hibition of microtubule assembly was observed when d was
phosphorylated by a combination of CK-1 and GSK-3 or A-
kinase and GSK-3. d phosphorylated by the latter combina-
tion of kinases was most potent in inhibiting microtubule
assembly (Fig. 1). When viewed by electron microscopy,
only an occasional microtubule was observed when the A-
kinase and GSK-3 were acting in combination (Fig. 2). We
also examined the binding of d to taxol-stabilized microtu-
bules (Table 1). When d was phosphorylated by CK-1,
GSK-3 or A-kinase acting alone, the subsequent binding of
the phosphorylated d to microtubules was decreased by V10^
13%. Like microtubule assembly seen in Fig. 1, the strongest
inhibition of binding of d to microtubules was observed when
d was phosphorylated by a combination of CK-1 and GSK-3
(V39%) or A-kinase and GSK-3 (V50%) (Table 1). These
data suggest that the inhibition of d function requires the
concerted actions of both PDPKs (such as GSK-3) and
non-PDPKs (such as A-kinase and CK-1).
3.2. Puri¢cation of 32P-labeled phosphopeptides of d
As described above, d phosphorylated by the combination
of A-kinase and GSK-3 was most e¡ective in inhibiting micro-
tubule assembly (Fig. 1) and inhibition of binding to micro-
tubules (Table 1). Hence, we chose to identify the sites phos-
phorylated in d by this combination of kinases. d
phosphorylated by GSK-3 alone was used as a control. As
outlined in Section 2, d (0.3 mg) was ¢rst incubated in the
absence or presence of A-kinase and non-radioactive ATP for
2 h. Then reaction mixtures were heated at 95‡C for 5 min to
inactivate A-kinase and centrifuged. GSK-3 and [Q-32P]ATP
were then added to the d, which is heat stable and is recovered
in the supernatant, and the incubation continued for another
4 h. d was then precipitated with trichloroacetic acid and
digested with trypsin. After trypsin digestion, 32P-labeled pep-
tides were isolated by FeCl3 a⁄nity column chromatography.
The recovery of 32P peptides was about 97% for d phosphoryl-
ated by a combination of A-kinase and GSK-3 (Fig. 3a), and
about 87% for d phosphorylated by GSK-3 alone (Fig. 3b).
The 32P-labeled peptides eluted from FeCl3 a⁄nity column
were pooled, lyophilized and resuspended in 150 Wl of 0.1%
TFA and further puri¢ed by reverse phase liquid chromatog-
raphy (RPLC) using C18 column previously equilibrated in
0.1% TFA. Eight major radioactive peaks which contained
phosphorylated d sequences (labeled I^VIII) could be resolved
on RPLC for A-kinase plus GSK-3 preparation (Fig. 4a).
Under identical conditions, four radioactive d peptides (la-
beled IX^XII) were seen in GSK-3 alone (control) (Fig. 4b).
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Table 1
Binding to microtubules of d3L before and after phosphorylation by
di¡erent kinases
d phosphorylated by % d bound
None 94 þ 5.2
CK-1 87 þ 6.1
GSK-3 86 þ 4.6
A-kinase 81 þ 10.1
CK-1+GSK-3 61 þ 5.2
A-kinase+GSK-3 50 þ 6.6
Taxol-stabilized microtubules (0.4 mg/ml) were incubated with d (10
Wg/ml) for 30 min at 37‡C. Microtubule-bound and unbound d were
separated by centrifugation at 50 000Ug for 30 min at 32‡C over 125
mM sucrose cushion. The pellet and the supernatant dried in a speed-
vac concentrator were resuspended in Laemmli sample bu¡er and
electrophoresed on a 10% SDS-polyacrylamide gel. The blots were
developed with 92e and quantitated with the aid of a computerized
bioimage analyzer (Fuji BAS-1500). The data are expressed as
mean þ S.D. of nine values.
Fig. 2. Electron micrographs showing the products of the microtu-
bule assembly reaction negatively stained with phosphotungstic acid.
Aliquots of each sample (from Fig. 1) were taken at the steady state
of polymerization (V10 min) and stained negatively with 2% phos-
photungstic acid. A large mass of microtubules was seen in assem-
bly promoted by non-kinase treated d (panel a), CK-1 phosphoryl-
ated d (panel b), GSK-3 phosphorylated d (panel c) and A-kinase
phosphorylated d (panel d). Whereas only an occasional microtubule
was seen in the assembly promoted by CK-1 plus GSK-3 (panel e)
and A-kinase plus GSK-3 (panel f) treated d. Bar, 0.5 Wm.
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3.3. Phosphoamino acid analysis and sequential manual Edman
degradation of 32P peptides isolated by RPLC
Analysis of the phosphopeptide peaks by high-voltage elec-
trophoresis on thin-layer silicone plates revealed that peaks I^
V and IX contained both p-Ser and p-Thr, whereas peaks VI^
VIII and X^XII contained only p-Ser (Table 2). Amino acid
sequence analysis and sequential manual Edman degradation
of 32P fractions isolated by RPLC demonstrated that
S(p)GYS(p)S(p)PGS(p)PGT(p)PGSR, T(p)PPKS(p)PSSAK,
IGS(p)TENLK, IGS(p)LDNITHVPGGGNK, SPVVSGDT-
S(p)PR were the parent peptides containing the sites phos-
phorylated by A-kinase plus GSK-3, whereas T(p)PP-
S(p)SGEPPK, SPVVS(p)GDTSPR, IGS(p)TENLK and
IGS(p)LDNITHVPGGGNK were the peptides that contained
sites phosphorylated by GSK-3 alone. Peaks I and II had the
same sequence of Ser-198^Arg-209 (Fig. 5a); only peptide I
contained one more phosphorylation site (Ser-202) than pep-
tide II. Peaks III and IV shared the same sequence of Ser-195^
Arg-209. Peak IV might have been contaminated by a small
amount of peak III which smeared a little on the RPLC sep-
aration; ‘tailing’ of this type is not uncommon. Peaks V, VI,
VII and VIII represented d fragments of Thr-231^Lys-240, Ile-
260^Lys-267, Ser-396^Arg-406 and Ile-354^Lys-369, respec-
tively (Fig. 5a). Peaks IX^XII corresponded to the sequences
of Thr-181^Lys-190, Ser-396^Arg-406, Ile-260^Lys-267 and
Ile-354^Lys-369, respectively (Fig. 5b). Alignment of the
phosphorylated peptides of 32P-d by A-kinase plus GSK-3
demonstrated that the corresponding phosphorylated sites
were Ser-195, Ser-198, Ser-199, Ser-202, Thr-205, Thr-231,
Ser-235, Ser-262, Ser-356 and Ser-404. By the same procedure,
it was demonstrated that d phosphorylated by GSK-3 alone
generated sites at Thr-181, Ser-184, Ser-262, Ser-356 and Ser-
400 (Fig. 6).
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Fig. 3. FeCl3 a⁄nity column chromatography to separate non-phos-
phorylated peptides from phosphorylated ones. FeCl3 a⁄nity col-
umn was prepared as described in Section 2. The tryptic digests of
32P peptides in 0.1 M of acetic acid were applied to the column. ub
is the unbound and 0.1 M acetic acid wash fractions; 5.0, 6.3, 7.2,
8.5 and EDTA represent the fractions eluted from the column with
0.1 M sodium acetate, pH 5.0, 1% ammonium acetate, pH 6.3, 1%
ammonium acetate, pH 7.2, 1% ammonium acetate, pH 8.3 and 0.2
M EDTA, pH 8.0, respectively. The recovery of 32P in the pH 8.5
elutes was 97 þ 1% (panel a, A-kinase plus GSK-3) and 87% (panel
b, GSK-3 alone).
Fig. 4. 32P d fragments phosphorylated by A-kinase and GSK-3
(panel a) or GSK-3 alone (panel b) resolved on RPLC. The tryptic
digests of 32P-d (0.3^0.5 mg) eluted at pH 8.5 from FeCl3 column
were lyophilized, resuspended in 0.1% TFA and applied to C18 re-
verse phase column. Eight (panel a, A-kinase plus GSK-3) and four
(panel b, GSK-3 alone) major radioactive peaks were seen after the
separation, respectively. Peaks either not sequenceable or which did
not yield any identi¢able d sequence are not shown.
Table 2
Phosphoamino acid analysis of phosphopeptides separated by
RPLC
Phosphopeptides P-Ser P-Thr
I + +
II + +
III + +
IV + +
V + +
VI + 3
VII + 3
VIII + 3
IX + +
X + 3
XI + 3
XII + 3
Phosphoamino acid analysis of the phosphopeptide peaks resolved
from C18 (peaks I^VIII) or GSK-3 alone (peaks IX^XII). RPLC of
the tryptic digests of 32P-d phosphorylated by A-kinase plus GSK-3.
The phosphopeptide peak fractions shown in Fig. 4 were hydrolyzed
in 6 N HCl under N2 at 110‡C for 2 h. The hydrolysate was spotted
on a TLC plate and subjected to high voltage two-dimensional elec-
trophoresis followed by autoradiography to localize the 32P spots. The
positions of the phosphorylated amino acid standards were visualized
by ninhydrin staining. P-Ser: phosphoserine; P-Thr: phosphothreo-
nine.
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4. Discussion
Previously, we have shown that both non-PDPKs and
PDPKs phosphorylate d at some of the same sites as in
PHF-d as determined by immunoreactivity with phosphoryla-
tion-dependent d antibodies [28,44]. Furthermore, a prephos-
phorylation of d by various non-PDPKs (A-kinase, C-kinase,
CK-1 and CaM KII) served to stimulate a subsequent phos-
phorylation catalyzed by GSK-3. The highest level of such
stimulation was obtained with d3L that was prephosphoryl-
ated by A-kinase [28]. In the present study, we demonstrate
that the interaction of A-kinase with GSK-3 phosphorylates d
at 7 of 21 sites seen in PHF-d and markedly inhibits its ability
to promote in vitro assembly and binding to microtubules.
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Fig. 5. Identi¢cation of phosphorylation sites in the phosphopeptides separated by C18 RPLC of the tryptic digests of d. The 32P peptides
eluted from the RPLC column were subjected to sequential manual Edman degradation and amino acid sequence analysis to identify
phosphorylation sites as described in Section 2. Peaks I^VIII (a) are from A-kinase plus GSK-3 whereas peaks IX^XII (b) are from GSK-3
alone phosphorylation. The phosphorylated amino acids are indicated by asterisks in each peptide sequence.
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Our data showed (i) that A-kinase and GSK-3 combination
induced a 2- to 3-fold higher incorporation of 32P to d than by
GSK-3 alone; (ii) that phosphorylation of d with the com-
bined kinases led to a most potent inhibition of biological
activity of d ; and (iii) that the A-kinase and GSK-3 combina-
tion was capable of phosphorylating at least 10 sites (Ser-195,
Ser-198, Ser-199, Ser-202, Thr-205, Thr-231, Ser-235, Ser-262,
Ser-356 and Ser-404), whereas GSK-3 alone only phosphoryl-
ated 5 sites (Thr-181, Ser-184, Ser-262, Ser-356 and Ser-400)
under identical conditions. Among the 21 phosphorylation
sites (Ser-46, Ser-123, Ser-198, Ser-199, Ser-202, Ser-208,
Ser-210, Ser-212, Ser-214, Ser-217, Ser-231, Ser-235, Ser-262,
Ser-396, Ser-400, Ser-403, Ser-404, Ser-409, Ser-412, Ser-413
and Ser-422) found in Alzheimer PHF-d [14,18,39,45^49],
GSK-3 alone only phosphorylated Ser-262 and Ser-400,
whereas A-kinase and GSK-3 combination phosphorylated
Ser-198, Ser-199, Ser-202, Thr-231, Ser-235, Ser-262 and
Ser-404. These data suggest strongly that the interaction of
A-kinase with GSK-3 generates a more Alzheimer-like state of
d, indicating that it might be a potential system involved in
Alzheimer neuronal degeneration.
Phosphorylation of d at speci¢c sites inhibits the microtu-
bule assembly and reduces the binding of d to taxol-stabilized
microtubules (see Fig. 1 and Table 1). Dephosphorylation of
PHF-d restores the biological activity of d in promoting the
assembly of microtubules [8^10]. Recent studies report that
Ser-262 is a most potent site in regulating the binding of d
to microtubules [50]. Using recombinant d3L as a substrate
and reactivity with an antibody (12E8) to P-Ser-262 and P-
Ser-356, we recently found that phosphorylation at Ser-262
reduces only about 40% of microtubule binding as well as
causing a slight inhibition of microtubule assembly-promoting
activity of d [16]. In the present study, we further demon-
strated that a more e¡ective inhibition was seen when in ad-
dition to Ser-262, Alzheimer sites Ser-198, Ser-199, Ser-202,
Thr-231, Ser-235 and Ser-404 were also phosphorylated. It
implied that phosphorylation of d at the above mentioned
sites is involved in the regulation of biological activity of d.
Phosphorylation of d by individual kinases has been exten-
sively studied recently. It has been found that a kinase phos-
phorylates di¡erent ds at di¡erent rates and sites. Such a dif-
ferential phosphorylation exists between bovine d and human
d, even among human d isoforms [18,44,51]. For instance, A-
kinase phosphorylated d3 at Ser-214, Ser-324, Ser-356, Ser-409
and Ser-416 [52] whereas it phosphorylated d4L at Ser-262,
Ser-293, Ser-305, Ser-324 and Ser-356 [15]. Using bovine d (a
mixture of six isoforms) as substrate, it was found that GSK-
3K phosphorylated d at Ser-235 and Ser-404 [53] while GSK-
3L phosphorylated d at Ser-199, Thr-231, Ser-396 and Ser-413
[54]. In the present study, we have mapped biochemically the
sites phosphorylated in human d3L by GSK-3 and A-kinase
plus GSK-3 which have not been reported previously (see
Table 3).
In conclusion, the present study revealed that phosphoryla-
tion of d3L by various kinases di¡erentially inhibits the bio-
logical activity of d in microtubule assembly promoting and
microtubule binding. The most potent inhibition was seen in
the combined phosphorylation of d by A-kinase and GSK-3.
Under these conditions, at least seven Alzheimer-like phos-
phorylation sites (Ser-198, Ser-199, Ser-202, Thr-231, Ser-
235, Ser-262 and Ser-404) were obtained, while only two of
them (Ser-262 and Ser-400) were seen by GSK-3 alone. The
interaction of A-kinase with GSK-3 might be one of the most
potent systems responsible for the degeneration of neurons
with neuro¢brillary/d pathology in Alzheimer disease.
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Fig. 6. Alignment in d sequence of the phosphopeptides identi¢ed
from d phosphorylated by A-kinase plus GSK-3 (I^VIII) or GSK-3
alone (IX^XII). The amino acid numbering is according to d4L.
Amino acid residues Val-275^Ser-305 which comprise the second mi-
crotubule binding repeat and is missing in d3L are highlighted.
Table 3
Comparison of d sites phosphorylated by A-kinase, GSK-3 or by a combination of the two kinases
Kinases Phosphorylation sites d source Reference
A-kinase Ser-214, Ser-324, Ser-356, Ser-409, Ser-416 d3 Scott et al. [52]
A-kinase Ser-262, Ser-293, Ser-305, Ser-324, Ser-356 d4L Drewes et al. [15]
GSK-3(K) Ser-235, Ser-404 Bovine Yang et al. [53]
GSK-3(L) Ser-199, Thr-231, Ser-396, Ser-413 Bovine Ishiguro et al. [54]
GSK-3(K+L) Ser-181, Ser-184, Ser-262, Ser-400 d3L Present work
A-kinase+GSK-3 Ser-195, Ser-198, Ser-199, Ser-202, Thr-205, Thr-231, Ser-235, Ser-262 d3L Present work
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